GEN Exclusives

More »

GEN News Highlights

More »
Dec 21, 2007

Utek Enhances Open Innovation Services with $2.15M Pharmalicensing Buyout

  • Utek, a technology transfer company, agreed to acquire Pharmalicensing to extend its open innovation services and enhance its presence in the life science sector. The transaction is valued at $2.15 million and will be satisfied through the issuance of 153,967 Utek shares.

    Pharmalicensing assists firms in their R&D and business development programs through partnering and licensing. Based in York, England, the firm makes it possible for its approximately 200 clients to post descriptions of technologies that they are seeking to in-license or out-license.

    Utek expects to complete the transaction by early January, 2008. The acquisition will take effect through Utek Europe. “We believe that the acquisition of Pharmalicensing fits our strategy of becoming the leading provider of open innovation services and expands our existing operations within the U.K. market,” remarks Clifford M. Gross, Ph.D., Utek’s CEO.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »